Montanide ISA-51 (ISA-51)

Montanide ISA-51 is a clinical-grade vaccine adjuvant composed of a mixture of highly purified mineral oil and the surfactant mannide monooleate, designed to form a stable water-in-oil emulsion (National Cancer Institute [1]). It is functionally analogous to Incomplete Freund's Adjuvant (IFA) but is specifically formulated for human clinical use to enhance the immunogenicity of various antigens (PubMed: 12445651 [2]). The adjuvant functions primarily by creating a depot at the injection site, which protects the antigen from rapid degradation and allows for its slow, sustained release over time (Journal of Immune Based Therapies and Vaccines [3]). This sustained exposure facilitates the recruitment of antigen-presenting cells (APCs), such as dendritic cells and macrophages, to the site of injection, thereby promoting robust cellular and humoral immune responses (Vaccine [4]). Montanide ISA-51 has been widely investigated in clinical trials for therapeutic vaccines targeting various cancers, including melanoma and lung cancer, as well as infectious diseases like malaria and HIV (ClinicalTrials.gov [5]). While it significantly boosts the efficacy of peptide and protein-based vaccines, its use is frequently associated with local adverse events, such as injection site pain, swelling, and the formation of sterile granulomas (PubMed: 21530757 [6]).

Other names

Montanide ISA 51 VGIncomplete Freund's Adjuvant-like adjuvantISA 51Mannide monooleate-mineral oil emulsion

Acts as a delivery system that creates a depot at the injection site, ensuring slow release of the antigen and protecting it from degradation. It also recruits and activates antigen-presenting cells (APCs) to stimulate a robust T-cell and B-cell immune response.